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Objective: Renal artery percutaneous transluminal angioplasty (RPTA) and stenting (RAS) are accepted therapies for
selected patients with renovascular hypertension and chronic renal insufficiency. We evaluated the outcomes and
complications of RAS performed by vascular surgeons at our institution with modern low-profile systems.
Method: We retrospectively analyzed all RPTA and RAS procedures attempted with the use of low-profile systems from
June 2000 to September 2003. Eighty-two patients (96 arteries) with atherosclerotic renal artery stenosis were treated.
Indication for treatment was hypertension in 44 (54%) and chronic renal insufficiency in 38 (46%). Technical success,
complication rates, clinical success for control of hypertension or renal insufficiency, restenosis, and survival were
reviewed with a mean follow-up of 1 year.
Results: Ninety-three arteries were treated with stents, three with RPTA only. Primary technical success was 95%, with
98% overall technical success. Major complications occurred in 6.1% and minor complications in 1.2%. Hypertension was
improved in 81% at 1 year. Renal function was improved in 23%, stable in 53%, and worse in 24% at 1 year. Restenosis was
seen by routine duplex surveillance in 25% at 1 year. Restenosis associated with clinical deterioration and confirmed by
angiogram was seen in 10%. The overall 3-year survival was 83%.
Conclusion: RPTA/RAS can be performed with low-profile systems with excellent technical success, low complication
rates, and clinical outcomes that compare favorably with prior reports. ( J Vasc Surg 2005;41:46-52.)Renal artery percutaneous transluminal angioplasty
(RPTA) was introduced by Gruntzig1 in 1978. Initial
reports from uncontrolled studies demonstrated an im-
provement in blood pressure control in patients with reno-
vascular hypertension, and renal function in patients with
chronic renal insufficiency (CRI).2-4 Technical success of
RPTA was poor, however, and restenosis rates ranged from
27% to 100% at 1 year.5
In 1991, the use of metallic stents in the treatment of
atherosclerotic renal artery stenosis was reported and has
since been shown to improve technical success and reste-
nosis rates.5,6 Of the recently published series, the primary
success of renal artery stenting (RAS) ranges from 70% to
100%, with restenosis rates of 13% to 43% at 1-year.5,7-12
In the only randomized trial comparing endovascular
therapy with surgery, Weibull et al13 showed that RPTA
was preferable to surgery as a first-line therapy for renovas-
cular hypertension. Subsequently, because of lower mor-
bidity and mortality rates, endovascular interventions have
become more frequent than operative therapy and may
have lowered the threshold for treatment of symptomatic
atherosclerotic renal artery stenosis. RAS has been shown
to improve or cure hypertension in nearly 80% of patients.5
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46RAS has also been shown to slow the decline in renal
function in patients with CRI.14,15
The morbidity and mortality of endovascular interven-
tions are lower than operative therapy, but complications
rates are still significant. Beek et al16 reviewed complica-
tions of RPTA/RAS in 1997, before the use of low-profile
catheter delivery systems. Although some improvements
have been made in 0.035-in systems since Beek’s series,
there was a 10% incidence of “minor” complications, 10%
incidence of “severe” complications, and a 16% incidence
of “radiologic-technical” complications. In a review of the
literature of nearly 1000 patients in 13 series, they found
overall complication rates ranged from 10% to 66%.
In early reports, RPTA/RAS used 0.035-in guidewires
and 8F guiding catheters for treatment of the renal artery.
With the advent of lower profile systems (0.014-in and
0.018-in wires, micropuncture sets, 5F and 6F guiding
catheters, ultrathin angioplasty balloons and balloon-ex-
pandable stents) and embolic protection, the technique of
RAS continues to evolve. These devices offer the theoretical
advantage of decreased trauma caused by wires and cathe-
ters, including atheroembolic renal failure. This review
quantifies the outcomes and complications of RAS done
with low-profile systems. We report the results of our initial
series of low-profile RPTA/RAS, including technical suc-
cess, complications, survival, clinical outcomes, and reste-
nosis.
METHODS
We retrospectively reviewed all patients with angio-
graphically confirmed renal artery stenosis in whom an
attempt at RPTA or RAS was performed by vascular sur-
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includes all cases performed by vascular surgeons at Dart-
mouth-Hitchcock Medical Center to date, including the
initial “learning curve” procedures.
Patient selection. Patients with renal artery stenosis
were treated in accordance with the American Heart Asso-
ciation (AHA) guidelines.17,18 Indications included (1)
hypertension (systolic blood pressure  40 mm Hg, dia-
stolic blood pressure 90mmHg, or both) either resistant
to treatment with 3medications of different classes (includ-
ing a diuretic), or associated with medication intolerance or
a solitary kidney; and (2) chronic renal insufficiency (CRI)
(serum creatinine  1.4 mg/dL, according to hospital
standards) of unknown etiology.
Arteriography was performed on patients with a clinical
indication for therapy in whom a stenosis was identified by
a screening duplex scan (86%) or other imaging study such
as magnetic resonance arteriography or computed tomo-
graphic (CT) arteriography (14%). Duplex criteria used for
preoperative screening were a peak systolic velocity (PSV)
of more than 200 cm/sec or a renal-aortic ratio (RAR)
greater than 3.5.19 Patients with renal insufficiency were
pretreated with 600 mg oral N-acetylcysteine twice the day
before the procedure and again the day of the procedure.
Indications for RPTA/RAS were arteriographic steno-
sis greater than 75% or a pressure gradient across the
stenosis of more than 15 mm Hg. Efforts were made to
minimize the amount of contrast used (1 mL/kg non-
ionic contrast), particularly in patients with renal insuffi-
ciency. Bilateral stenosis was treated during the same pro-
cedure if contrast volumes could be maintained near this
level. Between June 2000 and June 2003, 96 arteries (3
occlusions, 93 stenoses) in 82 patients were treated: 44
(54%) patients were treated primarily for hypertension, and
38 (46%) were treated primarily for CRI.However, because
bilateral disease was more prevalent in those with CRI,
more renal arteries were treated for CRI (53%).
Technique. Percutaneous access via the common fem-
oral artery was obtained using a micropuncture technique
(20-gauge access needle, 0.018-in wire, and 5F sheath) to
minimize femoral trauma. A 0.035-in Wholey or J wire was
advanced through the sheath into the abdominal aorta.
Diagnostic arteriography was performed through a 5F flush
catheter. Indications for RPTA/RAS were arteriographic
stenosis of more than 75% or a pressure gradient across the
stenosis of more than 15 mm Hg.
If renal artery stenosis was confirmed, the 5F sheath was
upsized to 6F and a 6F left internal mammary artery guid-
ing catheter was advanced over the 0.035-in wire and
positioned at the origin of the renal artery. The patient was
administered intravenous heparin (100 U/kg). The
0.035-in wire was then exchanged for a 0.014-in or
0.018-in wire. Embolic protection was selectively used with
the Guardwire (Medtronic) temporary occlusion and aspi-
ration system (0.014-in). Indications for embolic protec-
tion were typically either a serum creatinine level of 2.0
mg/dL or more or a solitary kidney. The renal artery was
selected and the lesion crossed with the low-profile wire.Critical lesions (75%) were pre-dilated with a 3- 
20-mm low-profile monorail Gazelle balloon (Boston Sci-
entific). In arteries with a stenosis of less than 75%, a 4F
glide catheter was used to measure the pressure gradient
across the lesion. A Tuohy-Borst valve on the end of the
catheter allowed wire access to be maintained while the
catheter was pulled back across the lesion.
Lesions were preferentially treated with premounted
balloon-expandable stents with typical diameters of 5 to 6
mm. We typically size our stents to the diameter of the
adjacent healthy renal artery. We do not oversize or over-
dilate. Angioplasty alone (4 to 6 mm) was performed in
cases where the anatomy was unfavorable for stent place-
ment, such as at bifurcations.
After deployment, a completion arteriogram was per-
formed, and a 4F catheter was used to obtain a pressure
measurement across the stent. A residual stenosis (30%),
or pressure gradient (5 mm Hg) was treated with either
repeat angioplasty or a second stent if further coverage of
the lesion was required. Femoral closure devices were used
preferentially where appropriate.
If the device failed or the patient was not a candidate,
heparin was reversed and manual pressure held. Patients
who were not on clopidogrel preoperatively were given a
300-mg loading dose and then treated postoperatively for 1
month (75mg orally per day) along with aspirin, which was
continued indefinitely.
Technical success was defined on an intent-to-treat
basis as a residual stenosis of 30% or less and a pressure
gradient of 5 mm Hg or less. If the artery was successfully
treated during the initial procedure, it was considered a
primary technical success. If the artery could not be cannu-
lated from the femoral approach but was successfully
treated from a brachial approach at the same procedure (n
 7), this was also considered a primary technical success.
Patients who were brought back for a second attempt at a
later date, either for a different approach (eg, brachial) or to
limit contrast exposure (or both), were considered a sec-
ondary technical success if the artery was subsequently
treated successfully.
Outcomes. Procedural complications were classified
as major or minor in accordance with AHA standards.17
Follow-up office visits, with review of medication, blood
pressure, serum creatinine level (in those with CRI), and
renal duplex scan were obtained at 1 month postoperatively
and every 6 months thereafter. Results are reported at a
mean follow-up of 1 year, unless otherwise stated. Clinical
measures of blood pressure and renal function are reported
at last follow-up in accordance with AHA standards.17
● Improved blood pressure was defined as a diastolic pres-
sure of less than 90 and systolic pressure of less than
140 on the same or reduced number of medications.
Inability to meet these criteria was defined as a failure.
● Improved renal function was defined as a 20% or more
decrease in serum creatinine level, relative to baseline.
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creatinine level remained within 20% of baseline and
worse if it increased by 20% or more.
Restenosis was determined by duplex scanning with a
velocity criteria of PSV greater than 180 cm/s and a RAR
greater than 3.5.9 Arteriography was performed on patients
with duplex velocity criteria for stenosis if they had either an
elevated serum creatinine level, recurrent or worsening
hypertension, a solitary kidney, or a progressively rising
duplex velocity. Survival data were available on all patients
through the Social Security Death Index.
Statistical analysis. We reviewed patient demograph-
ics, comorbid disease, the indication for treatment, preop-
erative duplex characteristics, procedural details, technical
success, complications, clinical success, restenosis, and sur-
vival. Discrete variables are presented as proportions and
compared with the 2 test. Continuous variables are pre-
sented as mean  standard deviation and compared with
the Student t test. Survival, hypertension response, renal
function response, and restenosis were analyzed using
Kaplan-Meier life-table methods. The log-rank test was
used to compare these outcomes between groups. P  .05
was considered statistically significant.
RESULTS
Patients treated for chronic renal insufficiency were
more likely to be older, male, and have coronary artery
disease, diabetes, and bilateral disease compared with pa-
tients treated for hypertension alone (Table I). Concomi-
tant iliac stent placement for preexisting disease was per-
formed on 5 patients (hypertension, 3 patients; CRI, 2
patients). Concomitant endovascular abdominal aortic an-
eurysm repair was performed in 1 patient (hypertension).
Preoperative duplex data were available on 78 (81%) of
the 96 arteries treated. Arteries treated for renal insuffi-
ciency tended to have slightly higher velocities and renal
aortic ratios; however, this was not statistically significant
(Table II).
Most lesions (82%) were ostial or within the proximal 5
Table I. Demographics for 82 patients undergoing renal
angioplasty and stent placement according to indication
for treatment
HTN
(n  44)
CRI
(n  38) P
Age (years) 63  11 75  8 .001
Male gender 32% 73% .002
Coronary artery disease 37% 62% .014
Diabetes 16% 30% .1
Tobacco 85% 79% NS
Hypercholesterolemia 58% 68% NS
Peripheral vascular disease 45% 46% NS
Abdominal aortic aneurysm 23% 21% NS
Bilateral renal artery disease 32% 50% .018
HTN, Hypertension; CRI, chronic renal insufficiency; NS, not significant.mm of the main renal artery. Angiographic stenosis wascritical (75%) in 49 arteries. These were treated without
first obtaining a pressure measurement across the lesion.
Pressure measurements were obtained in the remaining 47
arteries. The mean pretreatment systolic pressure gradient
(aorta-to-renal artery) was 55 mm Hg and was similar for
both indications. Mean contrast volume used for the pro-
cedure was 106 mL (range, 40 to 320 mL) in the hyper-
tension group and 69 mL (range, 15 to 200 mL) in the
renal insufficiency group (Table II).
Stents were placed in 93 arteries (97%). A variety of
stents were deployed, including the NIR Royal, 60%
(Medinol, Ltd), Corinthian, 19% (Cordis Endovascular),
Genesis, 9% (Cordis Endovascular), Herculink, 5%
(Guidant), and others, 7%. Five arteries were treated with
two stents. Six arteries in 4 patients (hypertension, 3; CRI,
1) received PTA alone. Embolic protection was used in 26
arteries (27%).
Technical success. Overall primary technical success
was 95%. Primary technical success was achieved in all
patients treated for hypertension and 88% of patients
treated for CRI. Technical failure in all cases was due to an
inability to select the renal artery, usually because of acute
caudal angulation. These 5 patients with CRI were brought
back at a later date and underwent subsequent attempts via
the left brachial artery, 4 of which were successful (second-
ary technical success at 98%).
Complications. Complications occurred in 6 patients
(Table III). One minor complication (1.2%), a groin hema-
toma, did not require operative therapy or blood transfu-
sion but did prolong hospital stay by one day for observa-
tion. There were five major complications (6.1%).
Postoperative azotemia (serum creatinine increase  20%)
occurred in 3 patients (3.9%). Azotemia resolved sponta-
neously in 1 patient and in another after a stent was placed
in a contralateral stenosis on postoperative day 1. Acute
renal failure developed in 1 patient with a baseline serum
creatinine level of 2.5 mg/dL after a failed attempt at
stenting via femoral access. A stent was subsequently placed
via a left brachial approach, but the patient did not improve
and went on to require dialysis. None of these patients who
Table II. Characteristics of 96 renal artery stenoses by
duplex and arteriography according to indication for
treatment  SD
HTN
(n  45)
CRI
(n  51) P
Duplex
Peak systolic velocity
(cm/sec)
295  85 344  187 .11
Renal-aortic ratio 4.1  2.0 5.0  2.8 .1
Arteriogram
Ostial location 86% 96% .11
Systolic pressure
gradient (mm Hg)
54  34 56  36 NS
Contrast volume (mL) 106  57 69  45 .002
HTN, Hypertension; CRI, chronic renal insufficiency; NS, not significant.developed azotemia had embolic protection.
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parenchymal perforation with a guidewire. This was de-
tected by CT scan after the patient reported flank pain
postoperatively. The patient was transfused with 2 units of
packed red blood cells and was discharged on postoperative
day 5 without further incident. One patient had a myocar-
dial infarction and required urgent PTA of a coronary artery
bypass graft stenosis. There were no perioperative deaths
and no operative conversions.
Length of stay. Early in the experience, patients were
observed overnight prior to discharge. Patients were later
selectively observed for postoperative creatinine and blood
pressure changes. The mean length of stay was 1.3 days in
the hypertension group (range, 0 to 9) and 2.2 days for
patients in the CRI group (range, 0 to 12).
Survival. By life-table analysis, overall 3-year survival
was 83%. Three-year survival was 86% for patients treated
for hypertension and 81% for patients treated for CRI.
These differences were not statistically significant.
Hypertension response. Follow-up data on blood
pressure and renal function were available on 83 (98%) of
85 patients. In those patients treated for hypertension,
mean systolic pressure, diastolic pressure, and need for
antihypertensive medication significantly decreased (Table
IV). Although patients with CRI were not treated primarily
for hypertension, 66% were hypertensive. Follow-up blood
pressure data were available on 32 (86%) of these patients
and showed statistically significant decrease in diastolic
pressure and medication requirements (Table IV). At 1
year, 81% of patients had blood pressure improvement as
defined by AHA criteria (Fig 1).
Renal function response. The mean baseline serum
creatinine level was 2.1 mg/dL for all patients with CRI.
Baseline creatinine was slightly higher in patients who
received embolic protection, reflecting our selection bias
for the use of the Guardwire (Table V). Mean serum
creatinine was unchanged at follow-up for the group as a
whole as well as the protected and unprotected subgroups.
By Kaplan-Meier life-table analysis, 76% of patients exhib-
ited stable or improved creatinine at 1-year follow-up (Fig
2). At last follow-up, renal function was improved in 23%,
stable in 53%, and worse in 24%.
Restenosis. Follow-up duplex data were available for
78 (92%) of 85 patients. By duplex criteria, restenosis was
present in 25% at 1 year (Fig 3). Restenosis was symptom-
Table III. Complications in 82 patients undergoing
renal angioplasty and stenting
n %
Minor complications 1 1.2
Groin hematoma 1 1.2
Major complications 5 6.1
Azotemia 3 3.7
Perinephric hematoma 1 1.2
Myocardial infarction 1 1.2atic in 6 patients (7.7%) at a median of 160 days. Thesepatients underwent successful repeat angioplasty, with clin-
ical improvement and without complications. Two asymp-
tomatic patients, one with a solitary kidney and one with
duplex evidence of a progressive worsening restenosis, un-
derwent repeat arteriogram and angioplasty. Primary free-
dom from reintervention (all treated for clinically signifi-
cant restenosis) was 90% at 1 year. There was no difference
in restenosis between the hypertension and CRI groups.
DISCUSSION
The potential advantage of lower profile systems in
renal PTA/RAS is to facilitate technical success and reduce
complications. In this series, all but one lesion could be
crossed and treated with the 0.014-in or 0.018-in guide-
wires. Overall technical success was 98%. Major adverse
clinical events occurred in 6.1% of patients in the current
series. This compares favorably with other reports, even
though learning-curve patients were included in this series.
In a meta-analysis of RAS and RPTA, major complications
(excluding hematomas and puncture trauma) were seen in
11% of cases.5 Beek et al16 reported serious adverse events
in 10% of their patients and found a similar rate in a review
of 13 series. Most major complications were related to wire
or catheter trauma. These included retroperitoneal hema-
tomas, both secondary to femoral artery access and wire
perforation of the kidney, renal artery dissection, perfora-
tion, pseudoaneurysm, thrombosis, aortic atheroemboli,
operative conversions, and death.
The lower rates of major complications reported in the
current series with low-profile systems appear to be due to
fewer traumatic complications. In the current series, there
was one traumatic complication, a perinephric hematoma
(diagnosed by CT scan) presumably secondary to wire
perforation of the kidney, which resolved without operative
intervention. Since this case, we have changed to a 0.018-in
wire with a shorter, softer tip that allows for stent deploy-
ment with less wire in the renal artery.
Most of the major adverse events in this series were
renal insufficiency or failure. In 2 of these 3 cases, elevation
in serum creatinine was transient and resolved within 30
Table IV. Blood pressure and antihypertensive
medications (mean  SD) at baseline and at a mean
follow-up of 1 year after renal angioplasty and stenting
according to indication for treatment
Baseline Follow-up P
HTN (n  42)
Systolic BP (mm Hg) 171  32 144  24 .001
Diastolic BP (mm Hg) 88  19 76  9 .001
Meds (No.) 3.0  1.1 2.1  1.2 .001
CRI (n  32)
Systolic BP (mm Hg) 155  26 148  25 .3
Diastolic BP (mm Hg) 79  12 72  8 .006
Meds (No.) 3.0  1.2 2.4  0.9 .01
HTN, Hypertension; BP, blood pressure; CRI, chronic renal insufficiency;
NS, not significant.days. In some series, such cases are often not even reported
rve).
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complications in our patients were related to renal athero-
emboli during cannulation or were contrast induced. Em-
bolic protection was not used in any of the cases in which
this complication occurred. On the basis of previous re-
ports, one would expect the incidence of contrast-induced
azotemia to be approximately 2% to 5%.20
The incidence of minor complications in the current
series is very low, 1.2%, with the single event being a groin
hematoma. Minor adverse events occurred in approxi-
mately 11% of the cases Beek reviewed; most were access-
site hematomas. By using a micropuncture technique, ac-
cess can be confirmed before introducing larger sheaths.
This practice has likely helped minimize groin complica-
tions. Likewise, the use of small-diameter guiding catheters
(6F instead of 8F) reduces the overall size of the arterial
puncture and promotes more successful hemostasis after
catheters and sheaths are removed. We routinely used the
6F Perclose (Abbott Vascular) closure device, when appro-
priate. Although failures occurred that required groin com-
pression, no groin complications related to the Perclose
occurred in our patients undergoing RPTA/RAS.
Early results (mean follow-up of 1 year) indicate that
clinical outcomes are comparable to studies that used larger
profile systems.5,9,10 In themeta-analysis, hypertension was
cured or improved in 69% (39% to 73%) at a mean fol-
Fig 1. Proportion of patients with improvement in h
angioplasty/stenting according to indication for treatm
throughout, number of patients at risk included with cu
Table V. Change in serum creatinine level (mean  SD)
at mean follow-up of 1 year for patients with baseline
chronic renal insufficiency with and without embolic
protection
Baseline Follow-up P
Total (N  38) 2.1  0.9 2.1  1.0 NS
Embolic protection (n  16) 2.2  0.9 2.2  0.6 NS
No protection (n  22) 1.9  0.8 2.1  1.1 NS
NS, Not significant.low-up of 16-months (6 to 48 months), whereas 89% wereimproved in the current series.5 For patients with CRI,
renal function was improved in 30%, stabilized in 38%, and
worse in 32% in the meta-analysis; whereas in our series,
renal function was improved in 23%, stable in 53%, and
worse in 24%. Others have noted similar reductions in
medication requirement and blood pressure, as well as
stabilization of creatinine.5,6,21
In the current series, the Guardwire embolic protection
device was used selectively in patients with significantly
elevated creatinine or a solitary kidney (or both). The
practical advantage of the Guardwire is its low, 0.014-in
crossing profile, which is the lowest of the commercially
available embolic protection devices. Henry et al reported
the feasibility and safety of embolic protection in a series of
32 renal artery interventions.22
No controlled studies have been performed evaluat-
ing the value of embolic protection during endovascular
renal intervention. The current study was not designed
to address this question, and the overall number of
patients studied was too small to allow for comparison.
Our initial experience lends support to the assertion that
embolic protection can be performed safely and does not
appear to worsen short-term outcomes. Anecdotally,
large particles of atherosclerotic debris have been re-
trieved on several occasions. However, more data are
needed to determine if the additional cost of these
devices is warranted.
Restenosis based on duplex criteria was high—25% at 1
year by life-table analysis.We are currently investigating our
relatively high rate of restenosis. Our laboratory is certified
by the Intersocietal Commission for the Accreditation of
Vascular Laboratories, and we are very confident of the
pretreatment studies. Some have suggested that stents in
the carotid artery change the duplex criteria and that nor-
mal criteria overestimate the frequency of restenosis. We
are planning to investigate this for renal arteries.
The ultrasound criteria used to detect restenosis were a
PSV of 180 and a RAR of 3.5. These are more stringent
tension (HTN) after renal percutaneous transluminal
(Kaplan-Meier method, standard error less than 10%yper
entcriteria than that used for initial screening (200 or 3.5). We
rves).
ough
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comparison to historical controls, the one article that
looked critically at duplex restenosis (Yutan9) used the
same criteria of 180 and 3.5. Second, we wanted to capture
patients with ‘early’ restenosis.
All patients had initial (1 month) postoperative duplex
scans with normal, low velocities. We believe that an eleva-
tion to 180 cm/sec, given a prior normal velocity, repre-
sents stenosis. Most of our patients captured in this reste-
nosis group are probably “early,” as only 10% were
symptomatic and required repeat arteriogram and PTA.
Although the discrepancy between duplex findings of
recurrent stenosis and clinical recurrence is difficult to
explain, Yutan et al9 reported similar findings. In their
report, less than half of patients with duplex velocities who
met the criteria for stenosis developed recurrent symptoms.
This may imply an effect of the stent on traditional duplex
velocity criteria for renal stenosis, but this remains to be
Fig 2. Proportion of patients with stabilization or impr
nal angioplasty/stenting according to indication for tre
throughout, number of patients at risk included with cu
Fig 3. Freedom from duplex-detected restenosis an
(Kaplan-Meier method, standard error less than 10% thrinvestigated.In the meta-analysis, overall 1-year restenosis was 17%
but ranged from 0% to 39%, depending on the definition of
restenosis, length of follow-up, and whether duplex or
angiography alone was used.5 This wide variability under-
scores the inherit weakness of a meta-analysis for this topic.
The major limitation of this study is that it is a retro-
spective analysis of a single-center experience with relatively
short follow-up. Our comparisons are based on historical
controls—series that used 0.035-in systems. This is partic-
ularly true for the evaluation of embolic protection. We
plan to continue our practice of selective protection based
on the presence of atherosclerotic debris that is often seen
in the renal artery aspirate.
Many factors influence the technical success and com-
plication rates with percutaneous interventions, including
patient selection and the prior experience of the physicians
performing the procedures. The benefit of this report is that
it represents the entire experience of RPTA/RAS by a
ent in renal function after renal percutaneous translumi-
t (Kaplan-Meier method, standard error less than 10%
HTN, hypertension; CRI, chronic renal insufficiency.
ically significant restenosis requiring re-intervention
out, number of patients at risk included with curves).ovem
atmend clingroup of vascular surgeons who used a well-defined, uni-
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with percutaneous intervention in other arterial beds prior
to performing RPTA/RAS.
In summary, RPTA/RAS with low-profile systems may
reduce complication rates and improve technical success,
even during the learning curve of developing expertise in
renal artery PTA and stenting. Comparable to previous
reports that used larger profile systems, RPTA/RAS with
low-profile systems appears to have a better effect on reduc-
ing blood pressure and medication requirements, and a
similar effect on renal function in patients with CRI. Em-
bolic protection offers theoretical advantages; however,
longer follow-up is needed to determine the effectiveness of
these systems. Although restenosis rates by duplex criteria
are high and comparable with previous reports, almost all of
the patients maintained clinical benefit and those with
clinically significant restenosis could usually be managed
successfully with repeat angioplasty or stenting.
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